

## Learner Notification

### MED Learning Group

#### Targeting Tumors with High Mutational Burden: Treating Patients with Advanced Non-Melanoma Skin Cancers

May 31, 2023 – May 31, 2024

Online

### Acknowledgement of Financial Commercial Support

Regeneron Pharmaceuticals, Inc.

### Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

### Satisfactory Completion

Learners must listen to each self-directed audio recording while following along with the visual slides and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be viewed in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

### Joint Accreditation Statement



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### Nurses (ANCC) Credit Designation

Amedco LLC designates this activity for a maximum of 1.50 ANCC contact hours.

### Objectives - After Attending This Program You Should Be Able To

1. Incorporate immune checkpoint inhibitor therapy data into the management of patients with metastatic or locally advanced cutaneous squamous cell carcinoma.
2. Review the immune therapy data for patients with either metastatic or locally advanced basal cell carcinoma in the second-line setting.
3. Recognize and manage the treatment related adverse events associated with immune checkpoint inhibitor therapy in patients with non-melanoma skin cancers.
4. Describe the multidisciplinary team approach in the management of patients with locally advanced or metastatic basal cell or cutaneous squamous cell carcinomas.

### Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1--6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Commercial Interest: Relationship
Russie	Allen	NA
Felecia	Beachum	NA
Naomi	De Brito	NA
Reinhard	Drummer	Novartis, Merck Sharp & Dhome, Bristol-Myers Squibb, Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, Catalym, Second Genome, Regeneron, Alligator, T3 Pharma, MaxiVAX SA, Pfizer, touchIME: Consultant/Advisory
Chris	Drury	NA
Matthew	Frese	NA
Christina	Gallo	NA

Michael R.	Migden	Regeneron, Replimune, Sum Pharmaceuticals, Stamford Pharmaceuticals: Consultant, Contracted Research
Vishal A.	Patel	Regeneron, Sanofi, PhD Biosciences, Almirall, Jounce Therapeutics: Consultant, Regeneron, Sanofi, Almifall: Speakers Bureau, Avstera Therapeutics, Lazarus AI, Science 37: Stock Shareholder
Jo	Shultz	NA
Lauren	Welch	NA

Questions? Email [Certificate@AmedcoEmail.com](mailto:Certificate@AmedcoEmail.com)